Medtronic sets MiniMed exchange ratio at 4.5939
Medtronic plc has set the exchange ratio for its offer to swap up to 225,361,295 shares of MiniMed Group, Inc. common stock for its own shares at 4.5939 MiniMed shares per Medtronic share. The exchange is subject to proration if oversubscribed, with Medtronic potentially accepting up to 55,032,401 of its shares. The final ratio was announced on October 7, 2026.
How this was made
The 30-second read
Why it matters
By setting the final exchange ratio at 4.5939 and describing how oversubscription proration and a de minimis increase could affect acceptance quantities, the filing reduces uncertainty about consideration mechanics for both MDT and MINM holders.
Market read
Final exchange ratio and proration mechanics are disclosed, which can affect deal-arb positioning and valuation linkage between MDT and MINM.
What to watch
Traders should watch for deal execution risk beyond the ratio, including tender participation levels, proration outcomes, and any subsequent SEC filings or closing conditions not covered in this excerpt.
Background
The document is Amendment No. 2 to Medtronic plc’s Schedule TO issuer tender offer, amending the terms of its exchange offer for MiniMed Group, Inc. shares.
Ticker impact
Medtronic amends its issuer tender offer, setting the final exchange ratio at 4.5939 MiniMed shares per Medtronic share accepted.
Likely modest support or stabilization as the market prices the finalized exchange ratio and proration mechanics.
The filing discloses the capped final exchange ratio and acceptance quantities under oversubscription, which is directly relevant to deal economics but not a new bid price or completion certainty.
Market effects
Adds incremental clarity to medtech M&A deal mechanics, which can influence sentiment around other consolidation targets and exchange-offer structures.
Primarily impacts US-listed MiniMed holders and ADR/US trading of Medtronic, with limited broader regional spillover.
Cross-border structure (Irish issuer, US target) may modestly affect global medtech M&A risk perception but is unlikely to move broader indices.
Counterpoint
Because the ratio is capped and proration can reduce accepted shares, the market may already have priced much of the economics; incremental impact could be limited.
Key entities
- issuerMedtronic plc
Irish public limited company conducting an issuer exchange offer for MiniMed shares.
- targetMiniMed Group, Inc.
US Delaware corporation whose shares are exchanged in the tender offer.
- regulatory_filingSEC Schedule TO (Amendment No. 2)
Tender offer amendment disclosing the finalized exchange ratio and related mechanics.
